Exceptional antioxidant capacity and vitamin C delivery
Amla's antioxidant activity is among the highest of any food — with an ORAC value approximately 3x that of acai and 10x that of blueberries. Emblicanin A and B are unique tannins that release vitamin C slowly during digestion, providing sustained antioxidant protection over 6–8 hours versus the 2–3 hour window of isolated ascorbic acid supplementation.
Cardiovascular protection and lipid improvement
Multiple RCTs demonstrate Capros® significantly reduces LDL oxidation, lowers total cholesterol and triglycerides, improves endothelial function, and reduces inflammatory markers (CRP, IL-6). A key human study showed amla extract outperformed simvastatin (20 mg) for LDL oxidation protection — a primary driver of atherosclerosis.
Blood sugar regulation and anti-diabetic effects
Amla significantly reduces fasting and postprandial blood glucose via alpha-glucosidase inhibition, improved insulin receptor sensitivity, and pancreatic beta-cell protection. Emblicanins protect beta cells from oxidative and inflammatory damage — one mechanism underlying amla's traditional use in Ayurvedic diabetes management.
Telomere preservation and cellular aging
A landmark Capros® study demonstrated amla extract preserves telomere length in human cells exposed to oxidative stress — suggesting a direct anti-aging effect at the genomic level. Telomere shortening is a primary biomarker of cellular aging; amla's ability to reduce telomere attrition positions it as a foundational longevity ingredient.
Liver protection and detoxification support
Amla is hepatoprotective — its gallic acid and emblicanin content protects liver cells from toxin-induced damage, reduces liver enzyme elevations (ALT, AST), and supports phase I and II detoxification enzymes. Clinical studies confirm amla's liver-protective properties alongside its antioxidant and anti-inflammatory activity.
Emblicanin slow-release vitamin C delivery
Emblicanin A and B are hydrolyzable tannins that release gallic acid and vitamin C slowly during intestinal hydrolysis, producing a sustained-release vitamin C effect that maintains plasma ascorbate levels for 6–8 hours. This extended release profile improves vitamin C bioavailability and provides prolonged antioxidant protection compared to bolus ascorbic acid supplementation.
NF-κB and inflammatory cytokine suppression
Gallic acid and ellagic acid from amla inhibit NF-κB transcription factor activation, reducing IL-6, TNF-α, and CRP production. Simultaneously, amla polyphenols activate Nrf2, inducing endogenous antioxidant enzyme expression — providing dual anti-inflammatory and antioxidant pathway engagement.
Telomerase activity preservation
Capros® amla extract has been shown in cell studies to maintain telomerase activity and reduce oxidative telomere damage — preserving telomere length under conditions of chronic oxidative stress. This mechanism, operating through Nrf2-mediated oxidative stress reduction and direct DNA protective activity, represents a novel anti-aging mechanism for an Ayurvedic ingredient.
Randomized, placebo-controlled study comparing Capros® amla extract (500 mg/day) vs. simvastatin (20 mg/day) vs. placebo for LDL oxidation and atherogenic markers in adults with dyslipidemia.
Adults with dyslipidemia. 12-week comparative study.
Capros® produced significantly greater reduction in oxidized LDL than simvastatin, while achieving comparable reductions in total cholesterol and triglycerides. Capros® also reduced CRP significantly while simvastatin did not. No adverse events with Capros®.
Randomized controlled trial of amla fruit powder vs. glibenclamide (sulfonylurea) vs. placebo in 32 type 2 diabetic patients for 21 days.
32 T2DM patients. 21-day comparative intervention.
Amla at both tested doses significantly reduced fasting and postprandial blood glucose, comparable to the pharmaceutical sulfonylurea at the higher dose. No hypoglycemic episodes with amla. Cholesterol also reduced in amla group. Supports amla as a safer diabetic adjunct.